UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation
NYSE:UTI • US9139151040
Current stock price
35.58 USD
+0.25 (+0.71%)
At close:
35.58 USD
0 (0%)
After Hours:
This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTI Profitability Analysis
1.1 Basic Checks
- In the past year UTI was profitable.
- In the past year UTI had a positive cash flow from operations.
- In the past 5 years UTI has always been profitable.
- Each year in the past 5 years UTI had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of 6.44%, UTI is doing good in the industry, outperforming 73.97% of the companies in the same industry.
- UTI's Return On Equity of 15.98% is fine compared to the rest of the industry. UTI outperforms 75.34% of its industry peers.
- The Return On Invested Capital of UTI (8.69%) is better than 76.71% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for UTI is significantly below the industry average of 15.17%.
- The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- With a decent Profit Margin value of 6.28%, UTI is doing good in the industry, outperforming 65.75% of the companies in the same industry.
- UTI's Profit Margin has improved in the last couple of years.
- UTI has a Operating Margin of 8.38%. This is in the better half of the industry: UTI outperforms 67.12% of its industry peers.
- In the last couple of years the Operating Margin of UTI has grown nicely.
- UTI's Gross Margin of 49.62% is in line compared to the rest of the industry. UTI outperforms 54.79% of its industry peers.
- In the last couple of years the Gross Margin of UTI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. UTI Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTI is creating some value.
- Compared to 1 year ago, UTI has more shares outstanding
- UTI has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, UTI has an improved debt to assets ratio.
2.2 Solvency
- UTI has an Altman-Z score of 3.89. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of UTI (3.89) is better than 73.97% of its industry peers.
- UTI has a debt to FCF ratio of 6.28. This is a slightly negative value and a sign of low solvency as UTI would need 6.28 years to pay back of all of its debts.
- UTI's Debt to FCF ratio of 6.28 is fine compared to the rest of the industry. UTI outperforms 71.23% of its industry peers.
- UTI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.29, UTI perfoms like the industry average, outperforming 58.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 3.89 |
ROIC/WACC1
WACC8.68%
2.3 Liquidity
- A Current Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- UTI's Current ratio of 1.14 is in line compared to the rest of the industry. UTI outperforms 43.84% of its industry peers.
- UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- UTI's Quick ratio of 1.14 is in line compared to the rest of the industry. UTI outperforms 46.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. UTI Growth Analysis
3.1 Past
- The earnings per share for UTI have decreased by 0.00% in the last year.
- UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 65.96% yearly.
- Looking at the last year, UTI shows a quite strong growth in Revenue. The Revenue has grown by 12.59% in the last year.
- UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- UTI is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.89% yearly.
- The Revenue is expected to grow by 8.84% on average over the next years. This is quite good.
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. UTI Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 36.68, the valuation of UTI can be described as expensive.
- UTI's Price/Earnings ratio is in line with the industry average.
- UTI's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.78.
- With a Price/Forward Earnings ratio of 38.75, UTI can be considered very expensive at the moment.
- UTI's Price/Forward Earnings ratio is in line with the industry average.
- UTI is valuated expensively when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.68 | ||
| Fwd PE | 38.75 |
4.2 Price Multiples
- UTI's Enterprise Value to EBITDA is on the same level as the industry average.
- 60.27% of the companies in the same industry are more expensive than UTI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 121.3 | ||
| EV/EBITDA | 17.18 |
4.3 Compensation for Growth
- The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
5. UTI Dividend Analysis
5.1 Amount
- No dividends for UTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UTI Fundamentals: All Metrics, Ratios and Statistics
35.58
+0.25 (+0.71%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-05 2026-05-05
Inst Owners97.17%
Inst Owner Change0%
Ins Owners2.7%
Ins Owner Change3.2%
Market Cap1.96B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (7.98%)
Short Float %6.53%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-103.86%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.68 | ||
| Fwd PE | 38.75 | ||
| P/S | 2.29 | ||
| P/FCF | 121.3 | ||
| P/OCF | 25.28 | ||
| P/B | 5.83 | ||
| P/tB | 6.83 | ||
| EV/EBITDA | 17.18 |
EPS(TTM)0.97
EY2.73%
EPS(NY)0.92
Fwd EY2.58%
FCF(TTM)0.29
FCFY0.82%
OCF(TTM)1.41
OCFY3.96%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.56
Graham Number11.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 3.89 |
F-Score7
WACC8.68%
ROIC/WACC1
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
What is the profitability of UTI stock?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
What is the valuation of UNIVERSAL TECHNICAL INSTITUT based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 36.68 and the Price/Book (PB) ratio is 5.83.
Can you provide the expected EPS growth for UTI stock?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.